BeiGene CEO John Oyler On Investing In Biotech In China: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
BeiGene CEO John Oyler discusses what is missing in China’s venture capital environment if it truly wants to foster innovation. Based in Beijing, BeiGene’s lead product entered the clinic in 2013.
You may also be interested in...
As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?
SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.
Merck Serono Opens Bioanalysis Center In Beijing To Support Clinical Trials In Asia; Plans To Double Staff
SHANGHAI - Merck KGaA's biopharmaceutical arm Merck Serono SA opened Aug. 31 a new R&D laboratory in Beijing to establish bioanalysis capability that will support clinical trials in Asia. The site is on Chinese contract research organization Pharmaron's new campus in the Beijing Economic and Technological Development Area
Merck Invests In China Oncology Start-up BeiGene
Merck & Co. affiliate MSD has invested an undisclosed amount of debt and equity financing in the Beijing-based start-up biotech BeiGene, Ltd., BeiGene announced May 2